Myriad Genetics Inc. said that a study comparing the efficacy of six tests to detect the recurrence of breast cancer found EndoPredict to be superior to Genomic Health Inc.'s Oncotype Dx in predicting the long-term recurrence of breast cancer.
Myriad's EndoPredict is a second-generation, multigene test designed to predict recurrence in breast cancer patients. Oncotype is a first-generation test used for the same purpose.
The study was led by scientists at the Institute of Cancer Research in London and included 818 women with breast cancer. Distant recurrence of breast cancer was the primary endpoint and the median follow-up period was 10 years.
The study compared the power of six predictive signatures, including clinical treatment score, immunohistochemical markers, Oncotype Dx recurrence score, breast cancer index, NanoString Technologies Inc.'s Prosigna and EndoPredict.
Each of the three second-generation tests evaluated — breast cancer index, Prosigna and EndoPredict — outperformed Oncotype Dx in this cohort in predicting the recurrence of breast cancer in both node-negative and node-positive patients across both zero to 10 years and five to 10 years after surgery.